Авторлор жөнүндө
Даданова Гулзада Сапарбековна, врач-эпидемиолог, Республиканский центр иммунопрофилактики Министерства здравоохранения, Бишкек, Кыргызская Республика
Нурматов Зуридин Шарипович, доктор медицинских наук, руководитель Научно-практического центра по контролю вирусных инфекций Национального института общественного здоровья, Бишкек, Кыргызская Республика
Ишенапысова Гульбара Сатыгуловна, директор Республиканского центра иммунопрофилактики Министерства здравоохранения, Бишкек, Кыргызская Республика
Жумагулова Гульнара Джумадыловна, заместитель директора Республиканского центра иммунопрофилактики, Бишкек, Кыргызская Республика
Dadanova Gulzada Saparbekovna, epidemiologist, Republican Center for Immunoprophylaxis of the Ministry of Health, Bishkek, Kyrgyz Republic
Nurmatov Zuridin Sharipovich, Doctor of Medical Sciences, Senior Researcher, Head of the Scientific and Practical Center for the Control of Viral Infections of the National Institute of Public Health, Bishkek, Kyrgyz Republic
Ishenapysova Gulbara Satygulovna, Director of the Republican Center for Immunoprophylaxis of the Ministry of Health, Bishkek, Kyrgyz Republic
Zhumagulova Gulnara Dzhumadylovna, Deputy Director of the Republican Center for Immunoprophylaxis, Bishkek, Kyrgyz Republic
Даданова Гүлзада Сапарбековна, эпидемиолог, Саламаттыкты сактоо министрлигинин Республикалык иммунопрофилактика борборунун кызматкери, Бишкек, Кыргыз Республикасы
Нурматов Зуридин Шарипович, медицина илимдеринин доктору, улук илимий кызматкер, Улуттук коомдук саламаттыкты сактоо институтунун Вирустук инфекцияларды көзөмөлдөө боюнча илимий-практикалык борборунун жетекчиси, Бишкек, Кыргыз Республикасы
Ишенапысова Гүлбара Сатыгуловна, Саламаттыкты сактоо министрлигинин Республикалык иммунопрофилактика борборунун директору, Бишкек, Кыргыз Республикасы
Жумагулова Гүлнара Жумадыловна, Республикалык иммунопрофилактика борборунун директорунун орун басары, Бишкек, Кыргыз Республикасы
Шилтемелер
1. World Health Organization. Руководство ВОЗ по лабораторной диагностике кори и краснухи. 2007;
2. EXECUTIVE BOARD EB125/4 125th Session Global elimination of measles Report by the Secretariat. 2009;
3. Minta AA, Ferrari M, Antoni S, Lambert B, Sayi TS, Hsu CH, et al. Progress Toward Measles Elimination — Worldwide, 2000- 2023. MMWR Morb Mortal Wkly Rep. 2024 Nov 14;73(45):1036-42.
4. European Region reports highest number of measles cases in more than 25 years - UNICEF, WHO/Europe [Internet]. 2025 [cited 2025 Dec 8]. Available from: https://www.who.int/europe/news/item/13-03-2025-european-region-reports-highest-number-of- measles-cases-in-more-than-25-years---unicef--who-europe
5. In Focus: From surviving to thriving Supporting health and well-being throughout childhood and adolescence in Europe and Central Asia.
6. Kyrgyzstan: WHO and UNICEF estimates of immunization coverage: 2023 revision. 2024;
7. Popova AY, Smirnov VS, Egorova SA, Nurmatov ZS, Milichkina AM, Drozd IV, et al. Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population. Vaccines (Basel) [Internet]. 2025 Mar 1 [cited 2025 Nov 9];13(3):249. Available from: https://www.mdpi.com/2076-393X/13/3/249/htm
8. Andrus JK, Rota PA, Papania M, Bahl S, Durrheim DN, Kretsinger K, et al. Progress and Challenges in Measles and Rubella Elimination in the WHO European Region. Vaccines 2024, Vol 12, Page 696 [Internet]. 2024 Jun 20 [cited 2025 Nov 13];12(6): 696. Available from: https://www.mdpi.com/2076-393X/12/6/696/htm
9. Grant GB, Masresha BG, Moss WJ, Mulders MN, Rota PA, Omer SB, et al. Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016. Vaccine [Internet]. 2019 Sep 10 [cited 2025 Nov 9];37(38):5754. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7412823/
10. Crowcroft NS, Minta AA, Antoni S, Ho LL, Perea W, Mulders MN, et al. Global challenges and solutions to achieving and sus- taining measles and rubella elimination. Revista Panamericana de Salud Pública [Internet]. 2024 [cited 2025 Nov 9];48:e90. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11648097/
11. Winter AK, Lambert B, Klein D, Klepac P, Papadopoulos T, Truelove S, et al. Feasibility of measles and rubella vaccination pro grammes for disease elimination: a modelling study. Lancet Glob Health [Internet]. 2022 Oct 1 [cited 2025 Nov 9];10(10). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9557212/
12. Central Asia is a hot spot for measles - WHO data | Eurasianet [Internet]. 2025 [cited 2025 Dec 8]. Available from:https://eurasia net.org/central-asia-is-a-hot-spot-for-measles-who-data
1. World Health Organization. Руководство ВОЗ по лабораторной диагностике кори и краснухи. 2007;
2. EXECUTIVE BOARD EB125/4 125th Session Global elimination of measles Report by the Secretariat. 2009;
3. Minta AA, Ferrari M, Antoni S, Lambert B, Sayi TS, Hsu CH, et al. Progress Toward Measles Elimination — Worldwide, 2000- 2023. MMWR Morb Mortal Wkly Rep. 2024 Nov 14;73(45):1036-42.
4. European Region reports highest number of measles cases in more than 25 years - UNICEF, WHO/Europe [Internet]. 2025 [cited 2025 Dec 8]. Available from: https://www.who.int/europe/news/item/13-03-2025-european-region-reports-highest-number-of- measles-cases-in-more-than-25-years---unicef--who-europe
5. In Focus: From surviving to thriving Supporting health and well-being throughout childhood and adolescence in Europe and Central Asia.
6. Kyrgyzstan: WHO and UNICEF estimates of immunization coverage: 2023 revision. 2024;
7. Popova AY, Smirnov VS, Egorova SA, Nurmatov ZS, Milichkina AM, Drozd IV, et al. Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population. Vaccines (Basel) [Internet]. 2025 Mar 1 [cited 2025 Nov 9];13(3):249. Available from: https://www.mdpi.com/2076-393X/13/3/249/htm
8. Andrus JK, Rota PA, Papania M, Bahl S, Durrheim DN, Kretsinger K, et al. Progress and Challenges in Measles and Rubella Elimination in the WHO European Region. Vaccines 2024, Vol 12, Page 696 [Internet]. 2024 Jun 20 [cited 2025 Nov 13];12(6): 696. Available from: https://www.mdpi.com/2076-393X/12/6/696/htm
9. Grant GB, Masresha BG, Moss WJ, Mulders MN, Rota PA, Omer SB, et al. Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016. Vaccine [Internet]. 2019 Sep 10 [cited 2025 Nov 9];37(38):5754. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7412823/
10. Crowcroft NS, Minta AA, Antoni S, Ho LL, Perea W, Mulders MN, et al. Global challenges and solutions to achieving and sus- taining measles and rubella elimination. Revista Panamericana de Salud Pública [Internet]. 2024 [cited 2025 Nov 9];48:e90. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11648097/
11. Winter AK, Lambert B, Klein D, Klepac P, Papadopoulos T, Truelove S, et al. Feasibility of measles and rubella vaccination pro grammes for disease elimination: a modelling study. Lancet Glob Health [Internet]. 2022 Oct 1 [cited 2025 Nov 9];10(10). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9557212/
12. Central Asia is a hot spot for measles - WHO data | Eurasianet [Internet]. 2025 [cited 2025 Dec 8]. Available from:https://eurasia net.org/central-asia-is-a-hot-spot-for-measles-who-data
1. World Health Organization. Руководство ВОЗ по лабораторной диагностике кори и краснухи. 2007;
2. EXECUTIVE BOARD EB125/4 125th Session Global elimination of measles Report by the Secretariat. 2009;
3. Minta AA, Ferrari M, Antoni S, Lambert B, Sayi TS, Hsu CH, et al. Progress Toward Measles Elimination — Worldwide, 2000- 2023. MMWR Morb Mortal Wkly Rep. 2024 Nov 14;73(45):1036-42.
4. European Region reports highest number of measles cases in more than 25 years - UNICEF, WHO/Europe [Internet]. 2025 [cited 2025 Dec 8]. Available from: https://www.who.int/europe/news/item/13-03-2025-european-region-reports-highest-number-of- measles-cases-in-more-than-25-years---unicef--who-europe
5. In Focus: From surviving to thriving Supporting health and well-being throughout childhood and adolescence in Europe and Central Asia.
6. Kyrgyzstan: WHO and UNICEF estimates of immunization coverage: 2023 revision. 2024;
7. Popova AY, Smirnov VS, Egorova SA, Nurmatov ZS, Milichkina AM, Drozd IV, et al. Collective Immunity to the Measles, Mumps, and Rubella Viruses in the Kyrgyz Population. Vaccines (Basel) [Internet]. 2025 Mar 1 [cited 2025 Nov 9];13(3):249. Available from: https://www.mdpi.com/2076-393X/13/3/249/htm
8. Andrus JK, Rota PA, Papania M, Bahl S, Durrheim DN, Kretsinger K, et al. Progress and Challenges in Measles and Rubella Elimination in the WHO European Region. Vaccines 2024, Vol 12, Page 696 [Internet]. 2024 Jun 20 [cited 2025 Nov 13];12(6): 696. Available from: https://www.mdpi.com/2076-393X/12/6/696/htm
9. Grant GB, Masresha BG, Moss WJ, Mulders MN, Rota PA, Omer SB, et al. Accelerating measles and rubella elimination through research and innovation - Findings from the Measles & Rubella Initiative research prioritization process, 2016. Vaccine [Internet]. 2019 Sep 10 [cited 2025 Nov 9];37(38):5754. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7412823/
10. Crowcroft NS, Minta AA, Antoni S, Ho LL, Perea W, Mulders MN, et al. Global challenges and solutions to achieving and sus- taining measles and rubella elimination. Revista Panamericana de Salud Pública [Internet]. 2024 [cited 2025 Nov 9];48:e90. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11648097/
11. Winter AK, Lambert B, Klein D, Klepac P, Papadopoulos T, Truelove S, et al. Feasibility of measles and rubella vaccination pro grammes for disease elimination: a modelling study. Lancet Glob Health [Internet]. 2022 Oct 1 [cited 2025 Nov 9];10(10). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9557212/
12. Central Asia is a hot spot for measles - WHO data | Eurasianet [Internet]. 2025 [cited 2025 Dec 8]. Available from:https://eurasia net.org/central-asia-is-a-hot-spot-for-measles-who-data
